Form 4: HeartSciences Director Awarded Stock Options
SEC Form 4
HeartSciences Inc. director Brian Szymczak was granted 6,000 stock options, vesting over three years, as part of the company's 2023 Equity Incentive Plan.
Summary
- Brian Szymczak, a director at HeartSciences Inc., was granted 6,000 employee stock options.
- The options were granted on January 16, 2025, with one-fourth vesting immediately.
- The remaining options will vest in equal increments every three months, contingent on continued service on the board.
- The options expire ten years from the grant date, unless terminated earlier according to the 2023 Equity Incentive Plan.
- The exercise price of the options is $3.33 per share.
Sentiment
Score: 7
Explanation: The document reflects a standard compensation practice, which is generally positive for aligning director and shareholder interests. There are no negative implications.
Positives
- The granting of stock options aligns the director's interests with those of the shareholders.
- The vesting schedule encourages continued service on the board.
Risks
- The value of the options is dependent on the future performance of the company's stock price.
- The options could be terminated earlier if the director leaves the board or under other conditions of the 2023 Equity Incentive Plan.
Industry Context
Stock options are a common form of compensation for directors and executives in publicly traded companies, aligning their interests with those of shareholders and incentivizing performance.
Comparison to Industry Standards
- The vesting schedule of one-fourth immediately and the remainder over three years is a fairly standard practice for stock option grants.
- The ten-year expiration period is also typical for such grants.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive incentive for the director to contribute to the company's success.
- The director is incentivized to increase the company's value to benefit from the options.
Key Dates
| Date | Description |
|---|---|
| 01/16/2025 | Effective date of the stock option grant and the date one-fourth of the options vested. |
| 01/21/2025 | Date the form was signed by Andrew Simpson, Attorney-in-fact. |
| 01/16/2035 | Expiration date of the stock options. |
Keywords
stock options, equity incentive plan, director compensation, vesting, HeartSciences, HSCS
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.